Impact of Endogenous E2 on SSI and GH Rebound

NCT ID: NCT02026973

Last Updated: 2016-03-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 62 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-31
• Study Completion Date: 2015-11-30

Brief Summary

Endogenous estrogens maintain growth hormone (GH) secretion in postmenopausal women by potentiating endogenous GH-releasing hormone (GHRH) drive and restraining somatostatin inhibition of GH release.

Detailed Description

Systemic concentrations of testosterone (Te), estradiol (E2), GH, IGF-I and IGFBP-3 decline in healthy aging individuals (1-3). Sex-steroid deprivation accentuates GH and IGF-I depletion, since Te and E2 stimulate GH and IGF-I production in older adults, hypogonadal patients of all ages, and patients undergoing gender reassignment (1,2,4). Tamoxifen blocks the effect of Te, suggesting involvement of E2 in GH's stimulation in men (5). E2 also stimulates GH secretion in women, putatively via the nuclear estrogen receptor (ER-alpha) (1,2,6,7). Because Te, E2 and GH fall with menopause, and Te is converted to E2 by aromatization in the body (8-10), we postulate that diminished Te concentrations, Te→E2 concentrations and low E2 mediate low GH output in older women. What remains unknown is whether the low E2 levels in postmenopausal women retain GH-stimulating effects. To test this notion would require blocking: (i) aromatase-enzyme activity, which mediates E2 synthesis from Te, and/or (ii) estrogen receptor-alpha, which transduces most of E2's stimulation of the GH axis.

Conditions

Normal Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

IM Placebo/Oral Placebo

IM placebo given once on Day 1; Oral placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.

Group Type: EXPERIMENTAL

Placebo

Intervention Type: DRUG

Somatostatin

Intervention Type: DRUG

IM Placebo/PO Anastrozole

IM placebo given once on Day 1; Oral Anastrozole 2.0mg pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.

Group Type: EXPERIMENTAL

Anastrozole

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Somatostatin

Intervention Type: DRUG

IM Fulvestrant/PO Placebo

IM Fulvestrant 250mg given once on Day 1; Oral Placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.

Group Type: EXPERIMENTAL

Fulvestrant

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Somatostatin

Intervention Type: DRUG

IM Fulvestrant/IM Anastrozole

IM Fulvestrant 250mg given once on Day 1; Oral Anastrozole pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.

Group Type: EXPERIMENTAL

Fulvestrant

Intervention Type: DRUG

Anastrozole

Intervention Type: DRUG

Somatostatin

Intervention Type: DRUG

Interventions

Fulvestrant

Intervention Type: DRUG

Anastrozole

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Somatostatin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. 60 healthy post-menopausal women (ages 55 to 80 y);

2. BMI 18-30 kg/m2

3. Community dwelling; and voluntarily consenting

Exclusion:

1. Recent use of psychotropic or neuroactive drugs (within five biological half-lives);

2. Obesity (outside weight range above);

3. Laboratory test results not deemed physician acceptable, cholesterol >250, triglycerides > 300, BUN >30 or creatinine > 1.5 mg/dL, liver function tests exceeding twice upper limit of normal, electrolyte abnormality, anemia;

4. Drug or alcohol abuse, psychosis, depression, mania or severe anxiety;

5. Systemic inflammatory disease;

6. Endocrinopathy, other than primary thyroidal failure receiving replacement;

7. Nightshift work or recent transmeridian travel (exceeding 3 time zones within 7 days of CRU admission);

8. Acute weight change (loss or gain of > 2 kg in 6 weeks);

9. Systemic illness

10. Unwillingness to provide written informed consent.

11. Allergy to anastrozole or fulvestrant (treatment drugs).

12. History or suspicion of breast cancer.

13. History of carcinoma (excluding localized basal cell carcinoma removed or surgically treated with no recurrence).

14. History of thrombotic arterial disease (stroke, TIA, MI, angina) or deep-vein thrombophlebitis.

15. History of CHF, cardiac arrhythmias, congenital QT prolongation, and medications used to treat cardiac arrhythmias.

16. Pre-menopausal status as determined by screening hormone measurements.

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Mayo Clinic

OTHER

Sponsor Role: lead

Responsible Party

Johannes D. Veldhuis

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Johannes Veldhuis, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Countries

United States

Other Identifiers

13-007623

Identifier Type: -

Identifier Source: org_study_id